SHH:688089
Cabio Biotech (Wuhan) Co., Ltd. · SHH · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 12:44 UTC
Last close
n/aCNY
Market data
8.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
2.8%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth11.7%49 of 100, above its sector
- Returns on capital8.8%74 of 100, above its sector
- Marginsn/anot placed
- Price8.9x69 of 100, above its sector
- Safety4.4484 of 100, above its sector
- What it pays out2.8%63 of 100, above its sector
- Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.53x
Its own average over 10 years, 368.7M.
- Profit1.42x
Its own average over 10 years, 101.1M.
- Free cash flow8.15x
Its own average over 10 years, 15.4M.
- Debt2.64x
Its own average over 6 years, 31.5M.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 8.15 times.
Sales is 1.53 times its own 10-year average; Profit is 1.42 times its own 10-year average; Free cash flow is 8.15 times its own 10-year average; Debt is 2.64 times its own 6-year average.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales against its own 10-year average1.53
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Profit against its own 10-year average1.42
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Free cash flow against its own 10-year average8.15
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Debt against its own 6-year average2.64
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Price against its own 0-year averagen/aMarket data
Not held.
- Source
- market
- Reported in
- CNY